$28.26
1.00% day before yesterday
Nasdaq, Jan 02, 10:00 pm CET
ISIN
IE00B56GVS15
Symbol
ALKS

Alkermes Plc Stock price

$28.26
-0.71 2.45% 1M
-0.74 2.55% 6M
+0.28 1.00% YTD
-0.49 1.70% 1Y
+2.55 9.91% 3Y
+8.84 45.49% 5Y
-45.37 61.62% 10Y
+9.45 50.21% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
+0.28 1.00%

Key metrics

Basic
Market capitalization
$4.7b
Enterprise Value
$3.6b
Net debt
positive
Cash
$1.1b
Shares outstanding
165.1m
Valuation (TTM | estimate)
P/E
14.0 | 18.8
P/S
3.1 | 3.1
EV/Sales
2.3 | 2.4
EV/FCF
7.2
P/B
2.7
Financial Health
Equity Ratio
71.3%
Return on Equity
25.1%
ROCE
19.3%
ROIC
26.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$1.5b | $1.5b
EBITDA
$364.7m | $386.1m
EBIT
$358.9m | $261.2m
Net Income
$339.3m | $248.8m
Free Cash Flow
$491.3m
Growth (TTM | estimate)
Revenue
1.1% | -3.8%
EBITDA
-19.4% | -9.7%
EBIT
-17.8% | -37.9%
Net Income
2.0% | -32.2%
Free Cash Flow
55.9%
Margin (TTM | estimate)
Gross
86.0%
EBITDA
24.0% | 25.8%
EBIT
23.6%
Net
22.3% | 16.6%
Free Cash Flow
32.3%
More
EPS
$2.0
FCF per Share
$3.0
Short interest
17.6%
Employees
2k
Rev per Employee
$870.0k
Show more

Is Alkermes Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Alkermes Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Alkermes Plc forecast:

19x Buy
83%
4x Hold
17%

Analyst Opinions

23 Analysts have issued a Alkermes Plc forecast:

Buy
83%
Hold
17%

Financial data from Alkermes Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
1,521 1,521
1% 1%
100%
- Direct Costs 212 212
16% 16%
14%
1,309 1,309
5% 5%
86%
- Selling and Administrative Expenses 661 661
4% 4%
43%
- Research and Development Expense 283 283
77% 77%
19%
365 365
19% 19%
24%
- Depreciation and Amortization 5.81 5.81
64% 64%
0%
EBIT (Operating Income) EBIT 359 359
18% 18%
24%
Net Profit 339 339
2% 2%
22%

In millions USD.

Don't miss a Thing! We will send you all news about Alkermes Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alkermes Plc Stock News

Neutral
Business Wire
4 days ago
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 44th Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, Jan. 13, 2026 at 10:30 a.m. PST (1:30 p.m. EST/6:30 p.m. GMT). The live webcast may be accessed under the Investors tab on www.alkermes....
Neutral
PRNewsWire
22 days ago
NEW YORK and NEW ORLEANS , Dec. 12, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Neutral
Seeking Alpha
29 days ago
Alkermes plc (ALKS) Presents at Evercore 8th Annual Healthcare Conference Transcript
More Alkermes Plc News

Company Profile

Alkermes Plc is a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include Aristada, which is used for the treatment of schizophrenia in adults; and Vivitrol, which is an injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Richard Pops
Employees 1,800
Founded 2011
Website www.alkermes.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today